Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LUCERO-BIO

Financiado

LUCERO BIO: Smart Optofluidic Isolation of Spheroids for Early-Stage Drug Discov...

LUCERO BIO: Smart Optofluidic Isolation of Spheroids for Early-Stage Drug Discovery Personalised medicine has become a key focus for the pharmaceutical industry as it can address global health challenges, such as strong variations of drug efficacy and toxicity linked to different patient subgroups. A major obstac... ver más

31/12/2025

Lucero

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

Lucero AB No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-10-26

HORIZON-EIC-2021-TRANSITIONOPEN-01: EIC Transition Open 2021 Scope:The EIC Transition Open aims at funding innovation activities that go beyond the experimental...

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

Lucero

1.30M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PLEC2023-010243 Herramientas diagnósticas, pronósticas y terapéuticas 539K€ Cerrado

BURnOUT Enabling efficient cell engineering leaving gene-expression... 150K€ Cerrado

MicroBeaCh Microfluidic Platform for Analyzing Sperm Flagellar Beating... 196K€ Cerrado

DropMicS Droplet printable microfluidic arrays for high-throughput sc... 196K€ Cerrado

iLoF iLoF: AI-augmented photonics to identify and quantify diseas... 4M€ Cerrado

RealCare Real-time biomarker detection systems for rapid medical deci... 9M€ Cerrado

Duración del proyecto: 38 meses Fecha Inicio: 2022-10-26
Fecha Fin: 2025-12-31

Líder del proyecto

Lucero AB No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 1M€

Descripción del proyecto Personalised medicine has become a key focus for the pharmaceutical industry as it can address global health challenges, such as strong variations of drug efficacy and toxicity linked to different patient subgroups. A major obstacle that pharmaceutical companies still face is the lack of enabling technologies to predict the effects of drug candidates in patients before entering clinical trials. In preclinical drug screening procedures, pharmaceutical companies demand that the technologies be selective in terms of detection and isolation of patient-derived 3D cell cultures while being scalable for high-throughput drug screening. Lucero fills this need by providing a novel cell-handling platform that combines microfluidics, optical tweezers and artificial intelligence. During our ERC PoC project, we developed an integrated benchtop device for in-vitro handling of single 3D cell cultures, in particular mini spheroids. Lucero will build on this achievement by expanding our prototype’s functionalities and adapting its design to automatically detect spheroid viability and fully automate their isolation, to match the drug screening workflow. By thoroughly testing the prototype’s performance and compatibility with our large European pharmaceutical partner on-site, we will mature our prototype to technological readiness level (TRL) 6. Based on their feedback we will increase our commercial readiness level (CRL) 6 and will be ready for the next acceleration phase. The intended result of this proposal is to introduce Lucero’s 3D cell-handling platform as an enabling tool for pharmaceutical companies to develop more effective near-patient treatments at a lower cost, as well as to establish Europe as a leader in precision healthcare.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores